29ba9008089c2b652e8520240e028c44ae724104
Home.md
| ... | ... | @@ -282,15 +282,15 @@ PMBL panel, Desch 2020, 10 |
| 282 | 282 | |[@paneaWholeGenomeLandscape2019](papers/paneaWholeGenomeLandscape2019)|BL|4|22 (55%)| |
| 283 | 283 | |[@hubschmannMutationalMechanismsShaping2021b](papers/hubschmannMutationalMechanismsShaping2021b)|DLBCL,FL|4|3 (9%)| |
| 284 | 284 | |
| 285 | -## Categorization |
|
| 285 | +## Categorization of genes |
|
| 286 | 286 | |
| 287 | -### Gene Tiers |
|
| 287 | +### Tiers |
|
| 288 | 288 | |
| 289 | 289 | **Tier 2** - Any gene described as significantly or recurrently mutated in one or more types of B-cell lymphoma is initially assigned to Tier 2 for that entity. The study describing the mutation of that gene in a particular entity is considered the originating study. |
| 290 | 290 | |
| 291 | 291 | **Tier 1** - Genes can transition to Tier 1 only after additional studies have demonstrated the recurrence of mutations in the same entity. |
| 292 | 292 | |
| 293 | -### Gene Designations |
|
| 293 | +### Additional Designations |
|
| 294 | 294 | |
| 295 | 295 | **aSHM** - Denotes genes as affected by aberrant somatic hypermutation (aSHM). Tier 1 and Tier 2 genes can have this designation, respectively abbreviated as *1-a* and *2-a*. For example, see [BCL7A](BCL7A). |
| 296 | 296 |